The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Sep. 03, 2019

Filed:

Mar. 13, 2015
Applicant:

University of Georgia Research Foundation, Inc., Athens, GA (US);

Inventors:

Shanta Dhar, Miami, FL (US);

Sean Marrache, Portland, OR (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/19 (2006.01); A61K 41/00 (2006.01); A61N 5/06 (2006.01); A61K 31/194 (2006.01); A61K 31/416 (2006.01); A61K 31/7004 (2006.01); A61K 47/54 (2017.01); A61K 47/69 (2017.01); A61N 5/067 (2006.01);
U.S. Cl.
CPC ...
A61K 31/19 (2013.01); A61K 31/194 (2013.01); A61K 31/416 (2013.01); A61K 31/7004 (2013.01); A61K 41/0042 (2013.01); A61K 41/0057 (2013.01); A61K 47/54 (2017.08); A61K 47/548 (2017.08); A61K 47/6907 (2017.08); A61K 47/6923 (2017.08); A61N 5/062 (2013.01); A61N 2005/067 (2013.01);
Abstract

A mitochondria targeted gold nanoparticle (T-3-BP-AuNP) decorated with 3-bromopyruvate (3-BP) and delocalized lipophilic triphenylphosphonium (TPP) cations to target the mitochondrial membrane potential (Δψm) was developed for delivery of 3-BP to cancer cell mitochondria by taking advantage of higher Δψm in cancer cell compared to normal cells. This construct showed remarkable anticancer activity in prostate cancer cells compared to non-targeted construct NT-3-BP-AuNP and free 3-BP. Anticancer activity of T-3-BP-AuNP was further enhanced upon laser irradiation by exciting the surface plasmon resonance band of AuNP and thereby utilizing a combination of 3-BP chemotherapeutic and AuNP photothermal effects. T-3-BP-AuNPs showed markedly enhanced ability to alter cancer cell metabolism by inhibiting glycolysis and demolishing mitochondrial oxidative phosphorylation in prostate cancer cells. Our findings demonstrated that mitochondria targeted and concerted chemo-photothermal treatment of glycolytic cancer cells with a single NP may have promise as a new anticancer therapy.


Find Patent Forward Citations

Loading…